<DOC>
	<DOC>NCT00187525</DOC>
	<brief_summary>This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.</brief_summary>
	<brief_title>A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Neary et al. Criteria for Frontotemporal Lobar Degeneration Age 40 80 CDR &lt; 3 or MMSE &gt; 15 English Speaking Study Partner Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>